Milestone Pharmaceuticals Q3 Earnings Call Highlights

ملخص مفصل

Milestone Pharmaceuticals (NASDAQ:MIST) plans to cut operating expenses by approximately 30% as it seeks to extend its cash runway while building sales of CARDAMYST and advancing a late-stage clinical trial. The company reported approximately 1,800 CARDAMYST prescriptions in the third quarter of 20